Additional Emerging HER2-Targeted Therapies in NSCLC

EP: 1.Value of Comprehensive Molecular Testing in NSCLC

EP: 2.Unmet Needs in HER2-Mutant NSCLC

EP: 3.Treatment of HER2-Mutant NSCLC: Consequences of Delays and Strategies to Improve Timely Initiation

EP: 4.Overview of HER2-Targeted Therapies in NSCLC

EP: 5.Mechanistic Role of Emerging Tyrosine Kinase Inhibitors (TKIs) in HER2-Mutant NSCLC

EP: 6.Efficacy and Safety of Zongertinib in Previously Treated and Treatment-Naïve HER2-Mutant NSCLC from Beamion LUNG-1 Trial

EP: 7.Evaluating TKI Efficacy and Safety in HER2-Mutant NSCLC from SOHO-01 Trial

EP: 8.Safety Considerations and Patient-Reported Outcomes of TKIs in HER2-Mutant NSCLC

EP: 9.Opportunities for Positioning TKIs as First-Line Therapy in HER2-Mutant NSCLC

Now Viewing

EP: 10.Additional Emerging HER2-Targeted Therapies in NSCLC

This episode discusses the expanding landscape of emerging HER2-targeted therapies in non-small cell lung cancer (NSCLC). Panelists describe a pipeline of new tyrosine kinase inhibitors (TKIs) beyond currently approved agents, noting that several are in clinical development and may further diversify available options. The conversation emphasizes the importance of ongoing research efforts to improve drug selectivity, reduce adverse events, and enhance brain penetration. The group considers combination therapeutic approaches, such as pairing TKIs with antibody-drug conjugates or immunotherapy, highlighting both their scientific rationale and the need for careful monitoring of toxicity profiles when combining agents. The discussion also touches on the evolving understanding of biomarkers, including the significance of HER2 mutations, HER2 protein overexpression, and gene amplification, as well as the potential for these factors to inform future patient selection. Overall, the episode underscores the dynamic progress in HER2-targeted NSCLC therapies and the continued need for research that guides optimal treatment strategies.